Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Histrelin (Supprelin LA / Vantas) vs Leuprolide (Lupron)
An educational, source-based comparison of Histrelin (Supprelin LA / Vantas) and Leuprolide (Lupron) — how each peptide works, what it's researched for, and what to know before going deeper.
GnRH agonist implant for central precocious puberty and prostate cancer.
Synthetic nonapeptide GnRH agonist delivered via a subcutaneous hydrogel implant providing continuous release for 12 months, desensitizing the pituitary and suppressing sex steroids.
- Central precocious puberty (Supprelin LA)
- Advanced prostate cancer (Vantas)
- • FDA-approved.
- • Implant site reactions and rare implant breakage at removal.
GnRH agonist used for prostate cancer, endometriosis, and precocious puberty.
Synthetic nonapeptide GnRH agonist. Continuous administration desensitizes pituitary GnRH receptors, suppressing LH/FSH and downstream sex hormone production (medical castration).
- Advanced prostate cancer
- Endometriosis
- Uterine fibroids
- Central precocious puberty
- Gender-affirming care
- • FDA-approved.
- • Initial testosterone flare; hot flashes, bone density loss with long-term use.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Histrelin (Supprelin LA / Vantas) | Histrelin implant in CPP | JCEM | 2007 | Sustained suppression of pubertal progression with single annual implant. |
| Leuprolide (Lupron) | Leuprolide in metastatic prostate cancer | NEJM | 1984 | Established equivalence to orchiectomy for androgen suppression. |
Side-effect & safety grid
- FDA-approved.
- Implant site reactions and rare implant breakage at removal.
- FDA-approved.
- Initial testosterone flare; hot flashes, bone density loss with long-term use.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Histrelin (Supprelin LA / Vantas) vs Leuprolide (Lupron) — Key differences
- Class: Histrelin (Supprelin LA / Vantas) is classified as GnRH Agonist · Endocrine, while Leuprolide (Lupron) is GnRH Agonist · Hormonal.
- Primary research focus: Histrelin (Supprelin LA / Vantas) — central precocious puberty (supprelin la); Leuprolide (Lupron) — advanced prostate cancer.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Oncology.